Association between obesity and Barrett’s esophagus in a Japanese population: a hospital-based, cross-sectional study

Table 2 Distributions of BMI, WC and WHR among cases and controls

A. Patients not taking PPIs
Adiposity measures	Controls	(%)	ESBE ≥ 1 cm	(%)	P value
BMI, kg/m²	21.8 ± 3.5	(17.2)^*	22.9 ± 2.64	(30.4)^*	0.11
WC, cm	80.3 ± 10.8	(23.4)^**	82.7 ± 8.68	(60.9)^**	<0.0001
WHR	0.87 ± 0.08	(49.6)^†	0.90 ± 0.04	(42.9)^†	0.55
B. Patients regularly taking PPIs
Adiposity measures	Controls	(%)	ESBE ≥ 1 cm	(%)	P value
BMI, kg/m²	22.4 ± 3.5	(19.5)^*	22.3 ± 3.3	(19.1)^*	0.94
WC, cm	80.8 ± 10.2	(29.8)^**	81.5 ± 10.1	(36.8)^**	0.27
WHR	0.88 ± 0.08	(46.7)^†	0.88 ± 0.06	(42.3)^†	0.54

BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, PPI proton pump inhibitor.
ESBE endoscopically suspected Barrett’s esophagus.
P values indicate the comparison in the prevalence between controls and ESBE ≥ 1 cm.
* The prevalence indicates body mass index ≥ 25 kg/m².
** The prevalence indicates a large waist circumference defined as ≥ 85 cm for males and ≥ 90 cm for females.
† The prevalence indicates a large waist-to-hip ratio defined as ≥ 0.9 for males and ≥ 0.85 for females.

ISSN: 1471-230X